Physician profile
Mark Levy
NPI 1194765297
$2,997.35
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,406 · 2020: $592.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $545.81 | 2019-2020 | |
| Pfizer INC. | $527.47 | 2019-2020 | |
| Amarin Pharma, INC. | $376.70 | 2019-2020 | |
| Amgen INC. | $291.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.45 | 2019-2020 | |
| Novo Nordisk INC | $240.04 | 2019-2020 | |
| Allergan, INC. | $140.97 | 2019 | |
| Merck Sharp & Dohme LLC | $133.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $109.61 | 2019 | |
| Astellas Pharma US INC | $99.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $52.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $31.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.15 | 2019 | |
| Lilly USA, LLC | $28.80 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.93 | 2019 | |
| Daiichi Sankyo INC. | $14.76 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.